Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06433427 Not yet recruiting - Aging Clinical Trials

Metabolic Dysregulation as Biomarker of Frailty: Role of the Mitochondrial Dysfunction

FRAMITO
Start date: May 29, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to evaluate the presence of mitochondrial dysfunction related to oxidative stress and its possible role in frailty, with and without multimorbidity, and to identify possible frailty biomarkers correlated with mitochondrial dysfunction. The main questions it aims to answer are: - What is the role of oxidative stress-related mitochondrial dysfunction in frailty, taking into account the interaction with multimorbidity. - What could be the specific biomarkers associated with mitochondrial dysfunction in the assessment of frailty. In order to reach the study goals, we will enroll three categories of older adults: - Non-Frail without Multimorbidity (NFWoM); - Frail with Multimorbidity (FWM); - Frail without Multimorbidity (FWoM). Each individual will undergo an assessment of frailty phenotype and multimorbidity, and the collection of blood samples to isolate Peripheral Blood Mononuclear Cells (PBMCs). The identification of frailty biomarkers in each group of participants will be performed by combining untargeted metabolomics-based approaches and functional studies on specific mitochondrial dysfunctions performed on PBMCs and their subpopulations. Multivariate statistical and machine learning techniques will characterize the three clinical phenotype groups based on molecular data.

NCT ID: NCT06433414 Not yet recruiting - Adverse Event Clinical Trials

PAUSE: Sick Day Medication Management Mobile App Study

PAUSE
Start date: May 2024
Phase: N/A
Study type: Interventional

Diabetes, heart disease and kidney disease have high morbidity and costs of care. Medications used to treat these conditions are effective. Yet, some have the risk of preventable adverse events when people are sick with the flu or stomach bug. These events include low blood sugar and acute kidney injury which can lead to extended hospital stays or death. Sick day medication guidance (SDMG) recommends stopping these medications temporarily when sick and restarted after symptoms subside. Unfortunately, many patients are not aware of these recommendations or find them hard to follow. The investigator's previous research has shown that there is a lack of SDMG education and patient resources. Research on the development, implementation, usability and efficacy of these resources is also limited. In developing a SDMG tool, the investigators surveyed patients who expressed interest in an electronic health (eHealth) tool. As a result, the PAUSE App provides a timely and innovative way to provide continuity of care to patients that is linked to each patients' unique pharmacy record. In the present pilot randomized control trial, the investigators will examine the outcomes of the PAUSE Initiative consisting of the PAUSE App and a SDMG educational handout. Approximately 16 Loblaw/Shoppers Drug Mart pharmacies across Alberta will take part. Patients of these pharmacies who take high-risk medications will be invited to participate. Each pharmacy will be randomized to provide their patients usual care (i.e. SDMG handout) or the intervention (i.e., PAUSE App + handout). Approximately 320 participants (20 per pharmacy) are expected to be recruited. The expected trial length is 9 months from recruitment to analysis. A simulated 'sick day' survey will be used to assess the fidelity and efficacy of the PAUSE Initiative. Feasibility of the study processes (i.e., recruitment, onboarding) will be assessed to inform a full-scale trial. The usability and acceptability of the PAUSE App will also be investigated. Pharmacists and participants will complete questionnaires and qualitative interviews to assess these outcomes. Additionally, PAUSE App user metrics will be collected. All participants will receive an honorarium for their time.

NCT ID: NCT06391151 Not yet recruiting - Pregnancy Clinical Trials

Effect of OSA Resulting From Chronic Tonsillitis on Pregnancy Outcomes

Start date: May 15, 2024
Phase:
Study type: Observational

This cohort study aims to investigate the impact of obstructive sleep apnea hypopnea syndrome (OSA) resulting from chronic tonsillitis on pregnancy outcomes. The hypothesis posits that chronic tonsillitis-induced OSA may exacerbate pregnancy complications and increase the risk of adverse pregnancy outcomes.

NCT ID: NCT06390436 Not yet recruiting - Chronic Disease Clinical Trials

Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis

SMOOTH
Start date: January 2025
Phase: Phase 4
Study type: Interventional

Uveitis and its complications are thought to account for 10 to 15% of preventable blindness in Western countries. The diagnosis of chronic non-infectious uveitis (CNUI) can be made after exclusion of pseudo uveitis or infectious uveitis, in the case of any persistent uveitis or uveitis with frequent relapses occurring less than 3 months after cessation of treatment. Adalimumab (ADA), an anti-TNFα monoclonal antibody, has marketing authorization and is widely used in the treatment of UCNI as a relay to corticosteroids. The use of ADA has been optimized, in particular through Therapeutic Drug Monitoring (TDM), based on the determination of serum ADA levels and anti-ADA antibodies. Recently, an article showed that a strategy of spacing ADA administrations in RA patients with concentrations >8 μg/mL was not inferior to standard.

NCT ID: NCT06324149 Not yet recruiting - Sarcopenia Clinical Trials

Age-related Conditions in the Context of Multimorbidity and Frailty: Relative Weight of Frailty in Determining the Course and Outcomes of Different Chronic Diseases and Viceversa

AGE-IT-FRAILTY
Start date: April 1, 2024
Phase:
Study type: Observational

Observational study. Participants of the FRASNET study (9th March 2017, Protocol No. 24/INT/2017) who were evaluated in 2016 and 2017 will be contacted to be re-evaluated with multidimensional visits as part of the present study in order to assess trajectories and biomarkers of frailty and sarcopenia. Moreover, are going to evaluate with the same multidimensional visits patients with mild cognitive impairment and dementia followed up at the Neurologic Unit of the San Raffaele Hospital.

NCT ID: NCT06287970 Not yet recruiting - Chronic Prostatitis Clinical Trials

TaVNS Improves the Symptoms of Patients With Moderate to Severe CP/CPPS

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP/CPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.

NCT ID: NCT06270875 Not yet recruiting - Chronic Illness Clinical Trials

Addressing Pain Through Navigator-Led Palliative Care Optimized for Heart Failure (ADAPT-HF)

ADAPT HF
Start date: June 30, 2024
Phase: N/A
Study type: Interventional

Using the MOST framework, factorial pilot design, and an iterative, community-based process, the purpose of this study is to pilot test to further develop and refine a palliative care (PC) intervention addressing pain of Black adults (age > 18) with advanced HF. Thirty-six persons with advanced heart failure (HF) will be randomized to receive one of 16 conditions (different combinations of navigator coach-delivered PC pain intervention components).

NCT ID: NCT06265662 Not yet recruiting - Chronic Disease Clinical Trials

A Digital Health Program for Non-Communicable Disease Prevention in a Workplace Setting in Thailand

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this quasi-experimental study is to test the effectiveness of a digital health program designed to prevent non-communicable diseases (NCDs) in employees within a workplace setting in Thailand. The main questions it aims to answer are: - Can a digital health program help participants lose weight? - Does the digital health program improve other health outcomes such as Body Mass Index (BMI), blood lipid levels (triglycerides and LDL), blood sugar levels (HbA1c or fasting plasma glucose), and blood pressure? Is the digital health program feasible and acceptable in the Thai workplace setting, as measured by participation rates, usage, and participant satisfaction? Participants will: - Attend four group health education sessions, each lasting one hour, scheduled over a six-month period. - Have unlimited access to individual chat consultations with a healthcare team, including doctors, dietitians, fitness coaches, and psychologists, available from 9:00 AM to 5:00 PM on workdays, excluding public holidays.

NCT ID: NCT06224556 Not yet recruiting - Older People Clinical Trials

A Personalized Prevention Program (PPP) Based on the Comprehensive Geriatric Assessment (CGA) for the Prevention of Multidimensional Frailty Related to Non-communicable Chronic Diseases (NCDs) in Older People

PrimaCare_P3
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

- Non-Communicable Diseases (NCDs) can accelerated the aging process and increase the frailty condition - The Comprehensive Geriatric Assessment (CGA) is the gold standard in the geriatric clinical context - Recently, in Italy the first Guidelines about the CGA in different settings for older people has been pubblicated - The CGA can identify older people at high risk of frailty who can benefit from a personalized prevention program - No studies has been investigated the effects of a personalized prevention program (PPP) based on the CGA in a primary care setting - The main hypothesis is that the CGA assessment can result in personalized prevention programs for older subjects in primary care settings with an effect in reducing the hospitalization rate and can be related to the biological paramters in NCDs

NCT ID: NCT06223997 Not yet recruiting - Long COVID Clinical Trials

The Impact of Long COVID on People Living With Pre-existing LTC

Start date: February 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about the impact of long COVID on people who have multiple (two or more) pre-existing long-term conditions (such as diabetes and asthma). The main question it aims to answer is: • How does long COVID impact the lives of adults living with multiple pre-existing long-term conditions and what are their rehabilitation needs? Participants will be asked to: - Take photos of things they feel represent the impact of long COVID on their day-to-day lives across seven days and, - Take part in an interview to discuss the impact of long COVID.